Prokidney

Prokidney Employees

12 people indexed:

Aparna Sahoo

VP, Head of Global Clinical Development

80g65w.ufqx4@x37gz1tu3.78t Sign up to see email

tj6x6f.gqtxt@qjxxlvjw7.5bt Sign up to see email
Bruce Culleton

Chief Executive Officer

6g780.zx4s72f6@qq9sj8sg5.376 Sign up to see email

z6svs.610z46qq@z8sqs36vg.a8z Sign up to see email
Darin J. Weber

Chief Regulatory Officer

17ufx.7.q7q4q@5xfxt9h67.z0u Sign up to see email

qqlxu.7.vtg40@1xthhlf9g.1u2 Sign up to see email
Emily Butler

SVP, Biometrics

140gf.6j5s7h@xzzhshwg1.h91 Sign up to see email

j0v2z.82s0q5@v97gqqqgf.094 Sign up to see email
James Coulston

Chief Financial Officer

b3x32.5qghvhw2@v7995q7b6.h04 Sign up to see email

q51vw.7460b5q7@74z3zz024.09g Sign up to see email
Joseph Stavas

SVP, Interventional Procedures and Patient Safety

8x4f7u.3w65x7@13x37bl2u.633 Sign up to see email

68q2q7.862g2z@6770zg72u.zzl Sign up to see email
Lucio Tozzi

SVP, Global Clinical Operations

8w38a.fv5jj@6g794x7w8.v7v Sign up to see email

4b5s1.aq909@93as56bgv.s90 Sign up to see email
Mary Weger

Chief People Officer

l9x9.0q2uq@zjhb076jh.5qf Sign up to see email

zh3u.t6069@xsq22zsx2.37q Sign up to see email
Nikhil Pereira-Kamath

Chief Business Officer

4fz85g.f1gg4x99b1ssqx@3x3q54s67.z1b Sign up to see email

vw479b.3xx5z0qu3wjfjj@b1g3j4b6g.u5v Sign up to see email
Richard Williams

SVP, Information Technology

xb3v9g5.718jjxgg@qf25tx301.u89 Sign up to see email

fjqt4ut.7x3j8gbx@2uz18646q.f6t Sign up to see email
Todd C. Girolamo

Chief Legal Officer and Secretary

4b47.s.99fj7q50@9qw46jsqb.2x5 Sign up to see email

bw7z.h.vx49qww8@sz550b7zf.fv8 Sign up to see email
Ulrich Ernst

EVP, Technical Operations

zaxg1v.9g6f0@av7013925.452 Sign up to see email

wwb713.gbzv7@64b6zzf02.10b Sign up to see email

Prokidney Company Information

ProKidney, based in Winston-Salem, NC, specializes in developing cell therapy candidates aimed at revolutionizing the treatment landscape for Chronic Kidney Disease (CKD). The company’s flagship product, REACT, is designed to halt the progression of CKD and potentially enhance kidney function. REACT, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, is currently undergoing a Phase 3 development program and multiple Phase 2 clinical trials targeting moderate to severe diabetic kidney disease. Additionally, a Phase 1 clinical trial is being conducted for REACT in subjects with congenital anomalies of the kidney and urinary tract (CAKUT). ProKidney estimates that approximately 38-39 million adults in the U.S. are affected by CKD, with about 17-18 million patients in the stage 3 or 4 categories. The company operates a GMP facility with multiple clean rooms, ensuring high standards of quality in line with GMP guidelines. ProKidney’s approach includes a patented technology that enhances manufacturing automation, supply chain, and medical delivery of cellular therapy products. REACT is a personalized treatment derived from a patient’s own kidney cells, which circumvents the need for immunosuppressive therapies typically required during kidney transplants.

Report inaccurate information